Von Eschenbach to China
This article was originally published in The Tan Sheet
FDA Commissioner Andrew von Eschenbach and Deputy Commissioner for International and Special Programs Murray Lumpkin met with China's minister of health and commissioner of China's food and drug agency as the two countries try to finalize a memorandum of agreement on the import safety of food, drugs and medical devices (1"The Tan Sheet" Aug. 20, 2007, p. 14). While withholding details of the MOA, Lumpkin noted that FDA's "preference is obviously not to have to catch problems in the products at our borders ... but prevent them at the source of their manufacturer." Von Eschenbach suggested the MOA will be finalized in early December, in time for HHS Secretary Mike Leavitt's visit to China. The meeting in Shanghai is the latest effort from the Bush administration's Interagency Working Group on Import Safety established in July...
You may also be interested in...
A spokesman at the Chinese embassy in Washington says China will intensify its food safety supervision as U.S. and Chinese officials in Beijing begin work on a memorandum of agreement on food and feed safety
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker